Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | Breast Cancer Research

Figure 4

From: Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

Figure 4

Estrogen suppresses induction of apoptosis by phosphatidylinositol-3-kinase pathway inhibitors. (a) Estradiol suppresses induction of apoptosis by BGT226. Cells cultured without or with 10 nmol/l 17β-estradiol (E2) were treated with 10 nmol/l BGT226, and apoptosis was measured after 4 days of treatment. Results are from at least three replicates for each treatment condition per cell line. Significant suppression of apoptosis by E2 is indicated (*P < 0.05). Suppression of phosphatidylinositol-3-kinase inhibitor-induced apoptosis by E2is dose dependent. Cells cultured without or with 10 nmol/l E2 were treated with the indicated concentrations of (b) BGT226 or (c) BKM120 and apoptosis was measured after 4 days of treatment. Results are from at least three replicates for each treatment condition per cell line. Significant induction of apoptosis in estrogen-deprived cells is indicated (*P < 0.05). Suppression of apoptosis by E2 in drug-treated and nontreated cells is indicated (#P < 0.05).

Back to article page